ATAD1 and prostate cancer: Altogether, ATAD1 is deleted at a high frequency across many tumor types, including in more than 25% of prostate cancer, 11% of melanoma, 7% of glioblastoma, and 4% of gastric adenocarcinoma (Figure 1C).